SB

Scott Biller

Executive Venture Partner at GV

Greater Boston

VC
Investor

Invests in

Stages:

Series B

  • Min Investment:

    $250,000.00

  • Max Investment:

    $50,000,000.00

  • Target Investment:

    $25,000,000.00

Skills

Drug Discovery
Medicinal Chemistry
Pharmaceutical Industry
Drug Design
Organic Chemistry
Oncology
Chemistry
Drug Development
Lead Change
Lifesciences
Pharmacology
Cancer
Biochemistry
ADME
Assay Development
CRO
Neuroscience
Organic Synthesis
Life Sciences

Education

Investments

Gate Bioscience

Series A

Total Funding: $60M

OMass Therapeutics

Series B

Total Funding: $95M

Work Experience

OT
OMass Therapeutics

2022

  • Board Member

    2022

G
GV

2021

  • Executive Venture Partner

    2021

    Searching for innovative investment opportunities in biopharma.

RT
ROME Therapeutics

2021

  • Board Member

    2021

GB
Gate Bioscience

2021

  • Board Observer

    2021

RT
Remix Therapeutics

2020

  • Board Member

    2020

FT
Foghorn Therapeutics, Inc

2020

  • Board Member

    2020

Vividion

2019 - 2024

  • Scientific Advisory Board member

    2019 - 2024

AP
Agios Pharmaceuticals

2010 - 2023

  • Scientific Advisory Board member

    2021 - 2023

  • Strategic Advisor

    2020 - 2021

  • Chief Scientific Officer

    2010 - 2019

DT
Denali Therapeutics

2015 - 2023

  • Scientific Advisory Board member

    2015 - 2023

NI
Novartis Institutes for BioMedical Research

2003 - 2010

  • Vice President, Global Discovery Chemistry

    2003 - 2010